ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model

Inflammation Research

Volumn 47, Issue 10, 1998, Pages 375-383

  Horizoe, T ^a   Nagakura, N ^a   Chiba, K ^a   Shirota, H ^a   Shinoda, M ^a   Kobayashi, N ^a   Numata, H ^a   Okamoto, Y ^a   Kobayashi, S ^a  

^a EISAI CO LTD   (Japan)

Author keywords

5 lipoxygenase; Antiinflammatory; Cyclooxygenase; ER 34122; Nonsteroidal anti inflammatory drugs

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CARRAGEENAN; ER 34122; ICOSANOID; INDOMETACIN; LIPOXYGENASE INHIBITOR; MYELOPEROXIDASE; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEUKEMIA CELL; MALE; MAST CELL LEUKEMIA; MICROSOME; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; ORAL DRUG ADMINISTRATION; OTITIS; PAW EDEMA; RAT; SEMINAL VESICLE; SHEEP; SYNOVIOCYTE; THICKNESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; BENZAMIDES; CARRAGEENAN; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EDEMA; HUMANS; INDOMETHACIN; LEUKOTRIENE B4; LEUKOTRIENE C4; LIPOXYGENASE INHIBITORS; MALE; MICE; MICE, INBRED BALB C; OTITIS; PEROXIDASE; PYRAZOLES; RATS; SHEEP; TUMOR CELLS, CULTURED;

EID: 0031784459     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050347     Document Type: Article

References (44)

1. Pullar T. Disease modifying drugs for rheumatoid arthritis: Yesterday's treatment today or today's treatment tomorrow? Br J Clin Pharmacol 1990;30:501-10.
2. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
3. 4 in inflammation. Crit Rev Immunol 1990;10:1-14.
4. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
5. Numata H, Okamoto Y, Shinoda M, Kobayashi N, Miyazawa S, Kawahara T, et al. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects. PCT Int. Appl. WO 96 14,302.
6. 2 from prostaglandin endoperoxides. Nature 1976;261:558-60.
7. Iizuka K, Akahane K, Momose D, Nakazawa M, Tanouchi T, Kawamura M, et al. Highly selective inhibitors of thromboxane synthetase. I. Imidazole derivatives. J Med Chem 1981;24:1139-48.
8. Auerbach BJ, Kiely JS, Cornicelli JA. A spectrophotometric microtiter-hased assay for the detection of hydroperoxy derivatives of linoleic acid. Anal Biochem 1992;201:375-80.
9. 2 using radioactive substrate. Anal Biochem 1986;154:676-81.
10. Baugh RJ, Travis J. Human leukocyte granule elastase: rapid isolation and characterization. Biochem 1976;15:836-41.
11. Mehdi S, Angelastro MR, Burkhart JP, Koehl JR, Peet NP, Bey P. The inhibition of human neutrophil elastase and cathepsin G by peptidyl 1,2-dicarbonyl derivatives. Biochem Biophys Res Commun 1990;166:595-600.
12. Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H. Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J 1992;285:603-11.
13. Kato Y, Ogawa K, Yamamoto S, Abe S, Kishi J, Hayakawa T. A novel TIMP-insensitive type IV collagen-degrading metalloproteinase from murine metastatic sarcoma cells. FEBS Lett 1990; 268:39-42.
14. Dayer J-M, Krane SM, Russell RGG, Robinson DR. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci USA 1976;73:945-9.
15. Van Arman CG, Begany AJ, Miller LM, Pless HH. Some details of the inflammations caused by yeast and carrageenin. J Pharmacol Exp Ther 1965;150:328-34.
16. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78:206-9.
17. 2 generation after administration of mild hyperosmotic saline solution into the gastric lumen. Eieosanoids 1990;3:23-7.
18. Marshall PJ, Griswold DE, Breton J, Webb EF, Hillegass LM, Sarau HM, et al. Pharmacology of the pyrroloimidazole, SK&F 105809-I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol 1991;42:813-24.
19. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991;256:929-37.
20. Fischer AR, McFadden CA, Frantz R, Awni WM, Cohn J, Drazen JM, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995;152:1203-7.
21. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF, The European zileuton study group for ulcerative colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997;112:718-24.
22. Weinblatt ME, Kremer JM, Coblyn JS, Helfgott S, Maier AL, Petrillo G, et al. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol 1992;19:1537-41.
23. Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-101.
24. 2 and cyclooxygenase-2. Eur J Biochem 1994;226:125-31.
25. Knott I, Dieu M, Burton M, Houbion A, Remacle J, Raes M. Induction of cyclooxygenase by interleukin 1: Comparative study between human synovial cells and chondrocytes. J Rheumatol 1994;21:462-6.
26. Hoffman T, Lee YL, Lizzio EF, Tripathi AK, Bonvini E, Puri J. Differential turnover of enzymes involved in human monocyte eicosanoid metabolism. Biochem Pharmacol 1992;44:955-63.
27. 4 production by stimulated whole blood: Comparative studies with isolated polymorphonuclear cells. Biochem Biophys Res Commun 1986;137:334-42
28. McMillan RM, Spruce KE, Crawley GC, Walker ERH, Foster SJ. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. Br J Pharmacol 1992;107:1042-7.
29. Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, et al. Bay X1005, a new inhibitor of leukotriene synthesis: In vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther 1993;267:51-7.
30. Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-y-1]-2, 2-dimethyl propanoic acid), a potent orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1992;70:799-807.
31. Argentieri DC, Ritchie DM, Ferro MP, Kirchner T, Wachter MP, Anderson DW, et al. Tepoxalin: A dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 1994;271:1399-408.
32. Bell RL, Bouska JB, Malo PE, Lanni C, Harris RR, Otis ER, et al. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J Pharmacol Exp Ther 1995;272:724-31.
33. Griswold DE, Marshall PJ, Lee JC, Webb EF, Hillegass LM, Wartell J, et al. Pharmacology of the pyrroloimidazole, SK&F 105809-II. Antiinflammatory activity and inhibition of mediator production in vivo. Biochem Pharmacol 1991;42:825-31.
34. Goulet JL, Snouwaert JN, Latour AM, Coffman TM, Koller BH. Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci USA 1994;91:12852-6.
35. Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 1997;185:1065-75.
36. Opas EE, Bonney RJ, Humes JL. Prostaglandin and leukotriene synthesis in mouse ears inflamed by arachidonic acid. J Invest Dermatol 1985;84:253-6.
37. Chang J, Carlson RP, O'Neill-Davis L, Lamb B, Sharma RN, Lewis AJ. Correlation between mouse skin inflammation induced by arachidonic acid and eicosanoid synthesis. Inflammation 1986;10:205-14.
38. Pignat W, Kienzle R, Böttcher I. How specific is the arachidonic acid-induced mouse ear oedema for lipoxygenase (LOX)- and cyclooxygenase (COX)-inhibitors? Agents Actions 1986;19:368-70.
39. Bouclier M, Luginbuhl B, Shroot B, Hensby CN. Arachidonic acid induced ear oedema in four strains of rats and mice: a comparative study of anti-inflammatory drugs. Agents Actions 1990;29:62-4.
40. Rao TS, Currie JL, Shaffer AF, Isakson PC. Comparative evaluation of arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation. Inflammation 1993;17:723-41.
41. Crummey A, Harper GP, Boyle EA, Mangan FR. Inhibition of arachidonic acid-induced ear oedema as a model for assessing topical anti-inflammatory compounds. Agents Actions 1987;20: 69-76.
42. Carlson RP, O'Neill-Davis L, Chang J, Lewis AJ. Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Agents Actions 1985;17:197-204.
43. Griswold DE, Webb E, Schwartz L, Hanna N. Arachidonic acid-induced inflammation: inhibition by dual inhibitor of arachidonic acid metabolism, SK&F 86002. Inflammation 1987;11:189-99.
44. Kotyuk B, Raychaudhuri A, DiPasquale G. Effect of anti-inflammatory compounds on edema formation and myeloperoxidase activity in the arachidonic acid-induced ear model in the mouse. Agents Actions 1993;39 Suppl.:C46-8.